• Filter By:
• Specialty
• Source
• Condition
• Cancer
• Infectious Disease
• Drug
• Training
• Management
• Procedure
• Therapy
• Vaccine
• Nutrition
• Country

Why Acupuncture Is Going Mainstream in Medicine
When the opioid addiction crisis began to surge in the U.S. about a decade ago, Dr. Medhat Mikhael spent a lot of time talking to his patients about other ways to heal pain besides opioids, from other types of medications to alternative treatments. As a pain management specialist at MemorialCare Orange Coast Medical Center in Fountain Valley, Calif., he didn’t anticipate leaving behind the short-term use of opioids altogether, since they work so well for post-surgical pain. But he wanted to recommend a remedy that was safer and still effective. That turned out to be acupuncture. “Like any treatment, acupuncture...
Source: TIME: Health - April 29, 2022 Category: Consumer Health News Authors: Elizabeth Millard Tags: Uncategorized healthscienceclimate medicine Source Type: news

Shenmayizhi Formula Combined with Ginkgo Extract Tablets for the Treatment of Vascular Dementia: A Randomized, Double-Blind, Controlled Trial.
Authors: Zhang H, Cao Y, Pei H, Wang H, Ma L, Wang Z, Diao X, Yang Y, Liu N, Wei Y, Li H Abstract Shenmayizhi formula (SMYZF) has been shown to have an effect on vascular dementia (VaD) in previous studies. The aim of this study was to evaluate whether a combination of SMYZF with Ginkgo extract tablets improves mild-to-moderate VaD. In this 12-week, randomized, double-blind, controlled study, we randomly assigned 196 patients with VaD (aged 50-85 years) to either the SMYZF group (n = 98) or the Ginkgo group (n = 98). All patients received Ginkgo extract tablets as a basic treatment, while the SMYZF group al...
Source: Evidence-based Complementary and Alternative Medicine - August 14, 2020 Category: Complementary Medicine Tags: Evid Based Complement Alternat Med Source Type: research

Efficacy and safety of Shenmayizhi decoction as an adjuvant treatment for vascular dementia: Study protocol for a randomized controlled trial
This study will provide evidences to evaluate the efficacy and safety of SMYZD in combination with GBEs in treatment of VaD, as well as the adjuvant role of SMYZD in combination. Trial is registered at Chinese Clinical Trial Registry: ChiCTR1800017359.
Source: Medicine - December 1, 2019 Category: Internal Medicine Tags: Research Article: Study Protocol Clinical Trial Source Type: research

Regulation of Tau Protein on the Antidepressant Effects of Ketamine in the Chronic Unpredictable Mild Stress Model
This study was carried out in accordance with the recommendations of the “Institutional Animal Care and Use Committee of China Medical University.” The protocol was approved by the “Institutional Animal Care and Use Committee of China Medical University.”Author ContributionsXWu and GW conceived and designed the experiments. YLi, RD, XR, WR, HYa, and YT performed the experiments. HYu, XZ, JY and XWa helped to analyze and interpret the data. GW drafted the manuscript. XWu, EX, YLu, and GZ provided critical revisions. All the authors reviewed and approved the final manuscript.FundingThe present stu...
Source: Frontiers in Psychiatry - April 29, 2019 Category: Psychiatry Source Type: research